Table 3 Ongoing phase 2 anti-amyloid therapy trials
From: Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Agent | Company | Synonyms | Therapeutic purpose | ClinicalTrials.gov identifier | Status |
|---|---|---|---|---|---|
ABBV-916 | AbbVie | N3pG-Abeta mAb | Immunotherapy (passive) | NCT05291234 | Recruiting |
ALZ-801 | Alzheon | valiltramiprosate | Small molecule | NCT04693520 | Active, not recruiting |
CT1812 (SHINE (COG0201) Study) | Cognition Therapeutics | Elayta | Small molecule | NCT03507790 | Recruiting |
CT1812 (START(COG0203) study) | NCT05531656 | Recruiting | |||
Varoglutamstat (VIVA-MIND) | Vivoryon Therapeutics AG. ADCS. NIA | PQ912 | Small molecule | NCT03919162 | Recruiting |
Varoglutamstat (VIVID) | NCT04498650 | Active, not recruiting |